Table 5. Estimate of the Marginal Effect of Plan Type on the Utilization of Diagnostic Breast Services For Patients Undergoing Subsequent Testing Relative to Plan Type With Lowest Out-of-Pocket Cost (ie, Dominantly Coinsurance)a.
Plan type and outcomes | Estimate (95% CI) | P value |
---|---|---|
Any subsequent breast image | ||
Balanced | −0.007 (−0.02 to 0.01) | .35 |
Dominantly copay | −0.024 (−0.04 to −0.01) | <.001 |
Dominantly deductible | −0.016 (−0.03 to −0.01) | .01 |
Diagnostic mammogram | ||
Balanced | −0.001 (−0.01 to 0.01) | .75 |
Dominantly copay | −0.011 (−0.02 to −0.00) | .02 |
Dominantly deductible | −0.008 (−0.02 to −0.00) | .04 |
Breast ultrasound | ||
Balanced | −0.000 (−0.01 to 0.01) | .94 |
Dominantly copay | −0.009 (−0.02 to −0.00) | .03 |
Dominantly deductible | −0.005 (−0.01 to 0.00) | .23 |
Breast MRI | ||
Balanced | −0.005 (−0.01 to −0.00) | <.001 |
Dominantly copay | −0.006 (−0.01 to −0.00) | <.001 |
Dominantly deductible | −0.006 (−0.01 to −0.00) | <.001 |
Breast biopsy | ||
Balanced | −0.009 (−0.02 to −0.00) | .05 |
Dominantly copay | −0.000 (−0.011 to −0.010) | .94 |
Dominantly deductible | −0.005 (−0.01 to 0.00) | .29 |
Abbreviation: MRI, magnetic resonance imaging.
Estimates adjusted for patient age, race and ethnicity, prospective Charlson Comorbidity Index, and state of domicile.